Theravance Biopharma (NASDAQ:TBPH) stock observed trading -10.81% off 52-week high price. On the other end, the stock has been noted 85.31% away from low price over the last 52-weeks. The stock disclosed a move of 13.38% away from 50 day moving average and 25.56% away from 200 day moving average. Moving closer, we can see that shares have been trading 3.17% off 20-day moving average. It has market cap of $1.90B.
On May 06, 2020, Theravance Biopharma (NASDAQ:TBPH) revealed financial results for the first quarter ended March 31, 2020. Revenue for the first quarter 2020 was $19.9 million. Operating loss was $72.5 million, or $57.2 million excluding share-based compensation expense. Cash, cash equivalents and marketable securities totaled $492.1 million as of March 31, 2020.
As we are each challenged by COVID-19 – personally and professionally, I want to thank our employees who have supported the communities we serve: the most vulnerable with respiratory illness and immune deficiencies, healthcare professionals across the globe and each other in extremely troublesome times. I could not be prouder, said Rick E Winningham, Chief Executive Officer. Theravance Biopharma moved to remote working conditions in early March 2020 for the vast majority of our workforce. Our past investment in technology infrastructure is enabling us to rapidly shift and service our business. Our geographic diversification of clinical trial sites as well as supply chain is minimizing impact on our clinical trial programs. The commitment of our lab-based personnel to work in our laboratories during this time has been crucial to continued progress of our pipeline programs.
Our commercial team remains focused on delivering YUPELRI to the COPD community – always a vulnerable community and especially during this pandemic – to both the people with COPD and the healthcare professionals that treat them; our team has been continuously available to support them with YUPELRI. As the only once-daily nebulized maintenance therapy for COPD, we believe YUPELRI has made a difference for the community during these challenging times.
The Cayman Islands based company Theravance Biopharma moved with change of 1.52% to $28.13 with the total traded volume of 150066 shares in recent session versus to an average volume of 465.88K. The stock was observed in the 5 days activity at -8.06%. The one month performance of stock was 21.32%. TBPH’s shares are at -7.63% for the quarter and driving a 10.44% return over the course of the past year and is now at 7.03% since this point in 2018. Right now the stock beta is 1.51. The average volatility for the week and month was at 6.54% and 5.63% respectively. There are 68.68M shares outstanding and 50.85M shares are floated in market.